Skip to main content

Grafa News and Videos — Page 1548

Latest

Grafa
Industrials

Atkore divests HDPE pipe business to Infra Pipes in strategic portfolio realignment

Atkore (NYSE:ATKR) announced on April 8, 2026, the sale of its High-Density Polyethylene (HDPE) pipe and conduit business to Infra Pipes, a prominent North American manufacturer of polyethylene pipeline solutions.

Read more: Atkore divests HDPE pipe business to Infra Pipes in strategic portfolio realignment
Grafa

Adagio Medical secures FDA nod to expand clinical trial for next-gen VT ablation system

Adagio Medical Holdings (NASDAQ:ADGM) announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT clinical trial.

Read more: Adagio Medical secures FDA nod to expand clinical trial for next-gen VT ablation system
Grafa
Mining

Odyssey Marine and AOMC announce $1B merger to create deep-sea minerals leader

Odyssey Marine Exploration (NASDAQ:OMEX) and American Ocean Minerals announced on April 8, 2026, that they have entered into a definitive merger agreement to combine their businesses, creating a premier platform for deep-sea critical minerals research and resource extraction.

Read more: Odyssey Marine and AOMC announce $1B merger to create deep-sea minerals leader
Grafa

Ontario court of appeal dismisses lawsuit against Barrick over North Mara mine

Barrick Gold (NYSE:B) welcomed a decisive legal victory on April 8, 2026, as the Ontario Court of Appeal dismissed an appeal brought by a group of Tanzanian residents concerning alleged human rights incidents near the North Mara gold mine.

Read more: Ontario court of appeal dismisses lawsuit against Barrick over North Mara mine
Grafa

FDA grants orphan drug designation to Plus Therapeutics’ REYOBIQ

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda).

Read more: FDA grants orphan drug designation to Plus Therapeutics’ REYOBIQ
Grafa

Bausch + Lomb secures FDA clearance for advanced vitrectomy technology

Bausch + Lomb (NYSE:BLCO), a leader in eye health, announced on April 8, 2026, that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Bi-Blade+ dual-port vitrectomy cutter and an advanced Adaptive Fluidics update for the Stellaris Elite® Vision Enhancement System.

Read more: Bausch + Lomb secures FDA clearance for advanced vitrectomy technology
Grafa

FDA grants breakthrough RMAT designation to United Therapeutics’ bioengineered liver assist product

United Therapeutics (NASDAQ:UTHR), a leader in regenerative medicine and organ manufacturing, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational miroliverELAP®.

Read more: FDA grants breakthrough RMAT designation to United Therapeutics’ bioengineered liver assist product

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift